Mumbai: Pharmaceutical and biotechnology major Wockhardt today said it has received approval from the US regulatory authority for marketing Midazolam injections, used in the treatment of sleeplessness and anxiety.
In a filing to the Bombay Stock Exchange, Wockhardt said it has received nod from United States Food and Drug Administration (USFDA) for marketing preservative-free version injections containing 1mg/ ml and 5 mg/ml Midazolam.
“Sterile products continue to be a priority area for Wockhardt in the US,” company Chairman Habil Khorakiwala said.
This is the fourth injection Abbreviated New Drug Application approval in two months and the 12th sterile product overall.
Wockhardt was trading at Rs105.60, up 1.15% in the early trade on the BSE.